WO2007080277A1 - Procede de preparation d' anticorps selectifs des recepteurs fc activateurs - Google Patents
Procede de preparation d' anticorps selectifs des recepteurs fc activateurs Download PDFInfo
- Publication number
- WO2007080277A1 WO2007080277A1 PCT/FR2006/002748 FR2006002748W WO2007080277A1 WO 2007080277 A1 WO2007080277 A1 WO 2007080277A1 FR 2006002748 W FR2006002748 W FR 2006002748W WO 2007080277 A1 WO2007080277 A1 WO 2007080277A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- region
- receptors
- tumors
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Definitions
- the present invention relates to a process for the preparation of a selective antibody to Fc receptors of the ITAM (immunoreceptor tyrosine-based activation motif) motif-promoting antibodies (FcRs), comprising the steps of obtaining monoclonal antibodies from a hybridoma, a heterohybridoma, or any animal, plant or human cell line, replacing each of the residues His 310 and His 435 (Kabat numbering) of the Fc region of said antibody by a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and then to select antibodies whose FcR patterned inhibitors ITIM (immunoreceptor tyrosine-based inhibition motif) is decreased by at least 30%, preferably by at least 50%, 70%, 80% or at least 90% over the same antibody possessing a region Fc native.
- FcRs Fc ⁇ RI (CD64, having isoforms A and B), Fc ⁇ RII receptor
- Fc ⁇ RIII (CD16, possessing isoforms A and B).
- the Fc ⁇ RRI and Fc ⁇ RIII receptors, as well as the Fc ⁇ RIIA receptor, are receptors qualified as "activators” because their activation, by via the ITAM motifs that their sequences or associated chain sequences comprise, allows the triggering of effector functions such as lysis of target cells.
- the Fc ⁇ RIIB receptors are qualified as "inhibitory” receptors because they inhibit the activation receptor transduction pathways via their ITIM motifs that their sequences comprise and negatively modulate effector mechanisms such as those of the ADCC. induced by activating FcRs or other surface molecules such as antigen receptor B (BCR) or growth factor receptors like c-kit.
- the diversity of FcR receptors in particular the existence of FcR activators and FcR inhibitors expressed on the same cells, is likely to modulate the efficacy of therapeutic antibodies, the commitment of FcR inhibitors counter-balancing the commitment of activating FcRs. .
- the Applicant in the document WO 2005/040216, describes antibodies whose primary sequence is modified, of particular interest in IgG4 replacement therapy, or to prevent graft rejection, or as anti-tetanus, diphtheria or directed drugs. against certain pathogens or toxins derived.
- the Applicant has surprisingly found that the modified antibody has retained its ability to induce an effector function dependent activating receptors, while it no longer has the ability to recruit inhibitory receptors.
- the Applicant has sought to develop a method for providing therapeutic antibodies whose effectiveness, that is to say the ability to activate immune effector cells, is not modulated or limited by the diversity of FcR receptors, in particular by inhibitory FcRs.
- the invention relates first of all to a method of preparing an antibody having the ability to recruit activating FcRs, but whose ability to recruit inhibitory FcRs is decreased relative to the same antibody having a native Fc region (c '). that is, whose Fc region selectively binds the Fc receptors of the activating antibodies (FcRs), comprising the following steps: a) obtaining monoclonal antibodies from hybridoma, heterohybridoma, or any animal, plant or human cell line, b) replacing each of the residues His 310 and His 435 (Kabat numbering) of the Fc region of the antibody with a residue chosen from lysine, alanine, glycine and valine , leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, c) selection of antibodies whose binding of the Fc region to the inhibitory FcR is decreased by at least 30%, preferably at least
- antibody means any antibody, regardless of its specificity and its isotype, provided that it comprises an Fc region or a region having the same functions and characteristics as the Fc region. Thus, it may be a whole antibody or an antibody fragment, for example an antibody Fc fragment, or a fusion molecule comprising at one of its ends an Fc region.
- the antibodies used in the method according to the invention may be IgG, that is to say any IgG1, any IgG2, any IgG3 (of G3m (s) or G3m (st) allotypes) and any IgG4, IgM, IgE, IgA or IgD, or a mixture of one or more them.
- the antibodies used in the method of the invention may be monoclonal or polyclonal. In the case of monoclonal antibodies, these antibodies can be chimeric, humanized, human or of animal origin.
- antibody also refers to an antibody composition, composed of antibody molecules having the same amino acid sequence, expressed in the same biological system, and comprising at least one pharmaceutically acceptable excipient or vehicle so that the composition may be formulated to allow pharmaceutical administration for prophylactic and / or therapeutic purposes.
- the sequences coding for the modified antibody of the invention are expressed in a suitable biological system (step b ').
- the term “same antibody” means an antibody not modified according to step b) of the process of the invention, and produced in the same biological production system as the modified antibody of the invention.
- the "same antibody” has the same native primary sequence (apart from the His 310 and His 435 residues, which have been modified in the antibody of the invention) and has been subjected to the same post-translational modifications as the antibody obtained. by the process of the invention, since it has been produced in the same biological system.
- the antibodies of step a) are obtained as monoclonal antibody compositions.
- Each monoclonal antibody composition is composed of antibody molecules having the same amino acid sequence, and therefore the same specificity, expressed in the same biological system.
- These compositions may, if appropriate, contain at least one excipient or a pharmaceutically acceptable vehicle so that these compositions may be formulated to allow pharmaceutical administration, for a prophylactic and / or therapeutic purpose.
- the antibodies of step a) comprise a native Fc region, that is to say that they have histidine residues at position 310 and 435 (Kabat numbering) of their Fc region.
- the Fc region of such antibodies binds to both activating and inhibitory receptors.
- the term "native Fc region of the antibody” means any unmodified Fc region, by any chemical or biotechnological processes, on the residues His 310 and His 435.
- Fc region is understood to mean Native of the antibody »any Fc region whose residues His 310 and His 435 have not been replaced, by chemical or biotechnological processes, a residue chosen from lysine, alanine, glycine, valine, leucine , isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine.
- the antibodies used in the invention may be chosen from anti-Ep-CAM, anti-KIR3DL2, anti-EGFR, anti-VEGFR, anti HER1, anti HER2, anti GD, anti GD2 Anti GD3, anti-CD20, anti CD-23, anti CD-25, anti-CD30, anti-CD33, anti-CD38, anti-CD44, anti CD52, anti CA125 and anti ProteinC, anti-HLA-DR, anti-virals: HBV, HCV, HIV and RSV, and more particularly from the antibodies of Table 1 below:
- trastuzumab Genentech anti HER2 Mammal Carcinoma: HERCEPTIN Licensed to Ovarian Cancer
- Epratuzumab Immuinedics / anti CD22 cancers Epratuzumab Immuinedics / anti CD22 cancers:
- the antibodies of the invention possess the ability to recruit, that is to say to bind by their Fc region, activating FcR receptors, but their ability to engage, that is to say to bind by their Fc region, the inhibitory FcR receptors, is decreased or abolished with respect to the same antibody possessing a native Fc region.
- activator FcR is meant Fc ⁇ RIIIA, Fc ⁇ RIIIB, Fc ⁇ RIIA, Fc ⁇ RIA and Fc ⁇ rib, Fc ⁇ R, Fc ⁇ RI and the human equivalent of Fc ⁇ RIV described in the mouse.
- inhibitory FcR is meant Fc ⁇ RIIB.
- the antibodies i.e., different antibody compositions, whose FcR binding is decreased relative to the same antibody having a native Fc region can be selected. This decrease can for example be measured by quantifying the number or percentage of cells expressing the FcRs to which the antibodies of the invention are bound, and comparing that number or percentage to that of the FcR expressing cells on which the antibodies having a native Fc region are bound .
- the antibodies that is to say different antibody compositions, whose binding to inhibitory Fc ⁇ R is abolished with respect to the same antibody possessing a region, are selected in step c).
- Native Fc according to a method similar to that described above.
- the antibodies prepared according to the method of the invention have an Fc region which binds to the activating FcRs but does not bind to the inhibitory receptors, whereas the same antibody produced by the same biological system but having a region
- Fc unmodified according to the method of the invention binds, by its Fc region, Fc ⁇ R activators and Fc ⁇ R inhibitors.
- the His 310 and His 435 residues are replaced by a lysine residue. In a preferred embodiment of the invention, the His 310 and His 435 residues are replaced by site-directed mutagenesis or by molecular evolution.
- residues His 310 and His 435 are modified by means of a chemical treatment, for example by DEPC treatment.
- an antibody with a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, and preferentially lysine has a major impact on fixation.
- the antibody thus modified with inhibitory FcRs, and in particular with Fc ⁇ RIIB and has a moderate effect on its binding to activating FcRs, and in particular to Fc ⁇ RIIIAs.
- the antibody of the invention thus modified no longer binds or almost no longer the human Fc ⁇ RIIB inhibitory receptor in an in vitro binding assay, whereas its attachment to the activating receptors Fc ⁇ RIIIA and Fc ⁇ RIIA is only very partially inhibited compared to the non-mutated antibody (see below).
- This mutated antibody is an antibody capable of engaging the activating receptors (Fc ⁇ RIIA and Fc ⁇ RIIIA) involved in the ADCC-type cytotoxicity by avoiding engaging the inhibitory Fc ⁇ RIIB.
- Such an antibody therefore makes it possible to induce an ADCC against target cells (red blood cells, tumor cells, allo-reactive cells, cells infected by microbial pathogens) without this ADCC being negatively modulated as a result of the Fc ⁇ RIIB commitment.
- target cells red blood cells, tumor cells, allo-reactive cells, cells infected by microbial pathogens
- Such an antibody also makes it possible to optimize the antigenic presentation by dendritic cells because the immune complexes containing this mutated antibody are captured only by the Fc ⁇ R activators expressed on the dendritic cells, without activating the Fc ⁇ RIIB inhibitors, also present on these cells. .
- This "differential" behavior on the activating and inhibitory receptors is an essential asset for using the antibodies of the invention in therapy, particularly in the context of cancer or infectious diseases. Indeed, such an antibody is capable of inducing ADCC mechanisms via the Fc ⁇ R activators without these being modulated negatively by the Fc ⁇ R inhibitors.
- the Applicant has found that such an antibody recruits only Fc ⁇ R activators on dendritic cells and does not recruit Fc ⁇ R inhibitors on the surface of the same cells.
- Fc ⁇ R inhibitors on the surface of dendritic cells has a negative effect on the maturation of these cells and on their ability to efficiently present an antigen to effector T cells, making these dendritic cells tolerogenic.
- the resulting antigenic presentation by the dendritic cells will be optimal and the activation effect of the immune response specific optimized.
- the Fc region of the antibody resulting from the process of the invention binds to the activating Fc receptors while it does not bind to the Fc inhibitory receptors.
- the antibody of the method of the invention does not recruit inhibitory Fc receptors, especially inhibitory Fc receptors expressed by B lymphocytes.
- the antibody of the method of the invention does not recruit the inhibitory Fc receptors but binds a molecule to the surface of B lymphocytes.
- the antibody of the invention does not recruit inhibitory Fc receptors but binds a molecule to the surface of tumor cells, in particular to the surface of B tumor cells.
- the antibody of the invention does not recruit the inhibitory Fc receptors but binds a molecule to the surface of the B-CLL tumor cells.
- the antibody of the invention does not recruit Fc receptors. inhibitors but binds the CD20 molecule to the surface of tumor lymphocytes of LLC-B.
- the antibody of the process of the invention binds to the Fc ⁇ RIII receptor (isoforms A and B) and / or to the Fc ⁇ RIIA receptor and / or to the Fc ⁇ RI receptor (isoforms A and B), while does not bind Fc ⁇ RIIB receptors (isoform B1 and B2).
- the Fc ⁇ RIIB receptor is the Fc ⁇ RIIB1 receptor.
- the receptors involved in the method of the invention are human receptors.
- the receptors of the Fc region of the antibodies are found on monocytes, macrophages, dendritic cells, NK cells, B lymphocytes, monocytes, macrophages, B lymphocytes.
- Fc antibodies are found on tumor cells, such as malignant melanoma cells, tumor B cells such as lymphomas, B-CLL cells (B-cell chronic leukemia) and myeloma cells.
- tumor B cells such as lymphomas
- B-CLL cells B-cell chronic leukemia
- myeloma cells binds, by its variable region, the CD20 molecule on the surface of tumor lymphocytes of LLC-B.
- Such an antibody of the invention does not recruit inhibitory Fc receptors, especially on the surface of tumor lymphocytes of LLC-B.
- the antibodies used in the method of the invention are monoclonal antibodies.
- These monoclonal antibodies can be produced by any suitable biological system, in the form of monoclonal antibody compositions, which compositions can contain at least one excipient or a pharmaceutically acceptable carrier so that these compositions can be formulated to allow pharmaceutical administration, in a prophylactic and / or therapeutic purpose.
- biological system animal or plant cell lines transfected with one or more vectors to express said antibody, transgenic non-human plants or animals, as well as any hybridoma, heterohybridoma.
- cells from cell lines transfected with a vector comprising the gene encoding said antibody, for example eukaryotic or prokaryotic cells, including mammalian cells, insect, ⁇ plants, bacteria or yeasts.
- eukaryotic or prokaryotic cells including mammalian cells, insect, ⁇ plants, bacteria or yeasts.
- rat myeloma cells such as YB2 / 0 (ATCC CRL 1662 0).
- CHO cells in particular CHO-K, CHO-LeclO, CHO-Lecl, CHO Pro-5, CHO dhfr- or other cell lines among Wil-2, Jurkat, Vero, Molt-4, COS- 7, 293-HEK, K6H6, NSO, SP2 / O-Ag 14 and P3X63Ag8.653, PERC6 or BHK.
- Another subject of the invention is the use of an antibody, each of whose residues His 310 and His 435 (Kabat numbering) of its Fc region has been replaced by a residue chosen from lysine, alanine and glycine.
- an antibody is used, each of whose His 310 and His 435 residues (Kabat numbering) of its Fc region has been replaced by a lysine residue.
- Another subject of the invention relates to the use of an antibody, each of whose residues His 310 and His 435 (Kabat numbering) is replaced by a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, or an antibody produced from the process of the invention for obtaining a medicament for treatment of cancer, and more particularly to the treatment of lymphomas, leukemias, myelomas, sarcomas, solid tumors such as breast carcinomas, colorectal tumors, pancreatic tumors, prostate tumors, stomach tumors, pulmonary tumors, ovarian tumors, cervical tumors uterus, eye tumors, thyroid tumors, tumors of the ENT sphere melanoma malignant, nerve tumors such as glioblastoma, and neuroblastomas.
- lymphomas leukemias, myelo
- an antibody is used, each of whose His 310 and His 435 residues (Kabat numbering) of its Fc region has been replaced by a lysine residue.
- Another subject of the invention is the use of an antibody, each of whose residues His 310 and His 435 (Kabat numbering) is replaced by a residue chosen from lysine, alanine, glycine, valine, leucine, isoleucine, proline, methionine, tryptophan, phenylalanine, serine or threonine, or an antibody produced from the process of the invention, for obtaining a medicament for the treatment of infectious diseases such as HIV infection, HBV, HCV, RSV (respiratory syncytial virus), SARS virus, rotavirus, influenza viruses, smallpox, bacterial infections such as Koch's bacillus, meningococci, Criptoccocus neoformans, Clostridium, bacteria responsible for Botulism, Anthrax
- anthrax tetanus, tuberculosis, and enterococcal infections.
- an antibody is used, each of whose His 310 and His 435 residues (Kabat numbering) of its Fc region has been replaced by a lysine residue.
- a final aspect of the invention relates to an antibody composition whose binding to inhibitory FcR is decreased by at least 30%, preferably by at least 50%, 70%, 80% or at least 90% or 100% with respect to the same antibody having a native Fc region.
- the composition of the invention is a composition whose Fc region of the antibodies has a capacity for binding to inhibitory receptors abolished with respect to the same antibody having a native Fc region.
- the composition of the invention is an anti-CD20 antibody composition.
- Figure 2 Effect of mutation of histidines 310 and 435 of anti-RhD mAb Tl25 (YB2 / 0) in lysines on the ability of the antibody to bind human RFc ⁇ .
- Figure 3 Effect of histidine mutation 310 and 435 of the anti-RhD mAb T125 (YB2 / O) on the ability of mAb to induce IL-2 production dependent on human RFc ⁇ lIIA.
- FIG. 4 Comparison of the binding of Tl25 (YB2 / 0), the double mutant T125 (YB2 / O) His 310 LyS / His 435 Lys and T125 (CHO) to human RFc ⁇ lIIA and RFcylIB.
- Figure 5 Effect of histidine mutation 310 and 435 of the anti-RhD monoclonal antibody T125 (YB2 / O) on the ability of the monoclonal antibody to induce a human RFc ⁇ IIIA-dependent ADCC relative to the wild-type antibody produced in YB2 / 0 and to the native antibody (wild-type) produced in CHO.
- FIG. 6 Surface representation of crystallographic structures of Fc fragments of T125 (YB2 / O) in the presence of Zinc (A) and the double mutant T125 H310K-H435K (YB2 / 0) (B).
- the YB2 / 0 (rat myeloma, ATCC line # CRL 1662) line transfected and producing the EMAB5 antibody (described in WO 2005/040216), which is a human IgG1 (Y) directed against the Rh antigen ( D), was adapted to culture in serum-free medium.
- EMAB5 was purified by affinity chromatography on Protein A Sepharose.
- the major glycanic structure is a biantennary-type oligosaccharide containing about 25% fucose.
- the purified EMAB5 antibody is dialyzed overnight against 50 mM Tris buffer, pH 8.0.
- the antibody solution adjusted to 50 mM CaC12 and 10 mM cysteine, is incubated
- the reaction is stopped by the addition of diisopropyl fluorophosphate (1 mM final).
- the hydrolyzate is dialyzed overnight against 50 mM Imidazole buffer, pH 7.8.
- the dialyzed hydrolyzate is contacted with Affarose-protein L at a rate of 1 ml of gel per 3.6 mg of antibody.
- the gel is mounted in a column and washed with 50 mM Imidazole buffer, pH 7.8.
- the effluent and wash buffer which contain the Fc fragments are pooled, concentrated by centrifugation on Vivaspin 20 using the conditions described by the manufacturer.
- the expression vector containing the cDNA encoding the amino acid sequence of the heavy chain of the anti-Rh (D) antibody EMAB5 served as a template for carrying out a double directed mutagenesis performed by PCR ("PCR-based site-directed mutagenesis "). The following four nucleotide substitutions were introduced:
- the heavy chain of the mutated antibody has the nucleotide sequence sequence SEQ ID NO: 1, and for peptide sequence SEQ ID NO: 2 (the mutated amino acids appear on the sequence SEQ ID NO: 2 at position 338 and 463 respectively for the amino acids Lys310 and Lys435).
- the numbering takes into account the leader sequences (338 and 463) or not (in the latter case, it is the so-called Kabat numbering which has been used: 310 and 435).
- YB2 / 0 cells co-transfected by electroporation with the mutated vector EMAB5-H-K338-K463-1 and the EMAB5-dhfr-K-SpeI vector encoding the light chain of the EMAB5 antibody, are cultured in RPMI medium supplemented with 5% dialyzed SVF, 0.5% G418 and 25 nM methotrexate (MTX). Clones secreting the highest levels of human IgG are cultured in 24-well plates in medium without MTX. The supernatants, harvested after 7 days of culture, are used to make the tests described below.
- RPMI medium supplemented with 5% dialyzed SVF, 0.5% G418 and 25 nM methotrexate (MTX).
- EXAMPLE 2 Effect of modification of histidines of the CH2 / CH3 interface of a monoclonal anti-RhD IgG1 by diethylpyrocarbonate (DEPC) on human IgG1 / RF0 ⁇ interactions.
- DEPC diethylpyrocarbonate
- T125 (YB2 / O) was treated with diethylpyrocarbonate
- DEPC modifies the histidine residues by creating a covalent bond between a nitrogen atom of the histidine ring and a carbon atom of the DEPC molecule.
- Monoclonal antibodies treated or not treated with DEPC are fractionated on a protein A-Sepharose column. Histidine 435 being important for the binding of IgG to protein A, the monoclonal antibody fraction treated with DEPC and not retained on protein A corresponds to IgG1 of which at least His 435 have been modified.
- Monoclonal antibodies Tl25 (YB2 / 0) untreated or treated with DEPC and not retained on protein A were compared for their attachment to different types of human RFc ⁇ ( Figure 1).
- the indicator cells Jurkat-huRFcylIIA (A) r K562 (B) IIA.1.6-huRFc ⁇ IIB1 (C) and Tf2-13 (D) are incubated with different concentrations of T125 (YB2 / O) treated or not treated with DEPC.
- T125 binds to RFc ⁇ lIIA at low concentration (from 0.05 ⁇ g / ml) and has a very high binding at 0.5 ⁇ g / ml (95% of positive cells).
- this monoclonal antibody is treated with DEPC, its binding is decreased at a high concentration (between 1 and 5 ⁇ g / ml) (approximately 90% reduction at 1 ⁇ g / ml) and becomes marginal at low concentration (between 0.025 ⁇ g / ml).
- Example 3 Effect of mutations of His 435 and His 310 residues of an anti-RM) monoclonal IgG1 on human IgG1 / RFcy interactions. Previous results indicate that modification of His residues of a monoclonal IgG1 affects its interactions with human RFcy. However, treatment with DEPC does not make it possible to determine which His have been modified.
- the indicator cells Jurkat-huRFc ⁇ IIIA (A), K562 (B), IIA.1.6-huRFc ⁇ IIB1 (C) and Tf2-13 (D) are incubated with different concentrations of T125 (YB2 / O) or of the double mutant Tl25 ( YB2 / 0) His 310 Lys / His 435 Lys.
- the binding of the mAbs is detected by F (ab ') 2 fragments of anti-human IgG (H + L) mice coupled to FITC).
- IL-2 production induced by 1, 5 and 10 ⁇ g / ml of mutated T125 (YB2 / O) is reduced by 61%, 53%, and 54%, respectively, compared to IL-2 release induced by the same doses of the non-mutated monoclonal antibody (Figure 3).
- RFc ⁇ IIIA + are stimulated during 151a at 37 ° C. by different concentrations of T125 (YB2 / O) or of the double mutant Tl25 (YB20) His 310 Lys / His 435 Lys, in the presence of rabbit F (ab ') 2 fragments anti-human IgG (H + L) allowing the aggregation of anti-RhD human monoclonal antibodies.
- IL-2 production by Jurkat-huRFc ⁇ IIIIA cells is then detected by ELISA. Induced IL-2 production in the presence of different concentrations of the two mAbs is reported as a percentage of that induced by 10 ⁇ g / ml T125 (YB2 / O)).
- T125 YB2O
- His 310 Lys / His 435 Lys is an antibody capable of engaging the activating receptors (RFc ⁇ lIA and RFc ⁇ IIIA), but whose ability to fix the inhibiting RFc ⁇ lIB is abolished.
- RFc ⁇ lIA and RFc ⁇ IIIA activating receptors
- T125 (YB2 / O), T125 (YB2 / 0) HiS 310 LyS / HiSH 435 LyS and T125 (CHO) mAbs to human RFcyIIIA (A), and RFcyIIBl (C) a was analyzed by indirect immunofluorescence.
- the indicator cells Jurkat-huRFc ⁇ lIIA (A), or HA.1.6-huRFc ⁇ lIB1 (C) are incubated with different concentrations of T125 (YB2 / O), T125 (YB2 / O) His 310 Lys / His 435 Lys and T125 (CHO) .
- the binding of the monoclonal antibodies is detected by human anti-IgG (H + L) mouse F (ab ') 2 fragments coupled to FITC. (B) and (D), the capacities of the monoclonal antibodies T125 (YB2 / 0), T125 (YB2 / O) His 310 Lys / His 435 Lys and
- the indicator cells Jurkat-huRFc ⁇ lIIA (B) or IIA.1.6-huRFc ⁇ IIB1 (D) are incubated with different concentrations of T125 (YB2 / O), or of Tl25 (YB2 / 0) His 310 Lys / His 435 Lys or T125 ( CHO), then with 40 ng / ml 3G8-PE (B) or 40 ng / ml AT10-FITC (D), respectively.
- T125 (CHO) which is more fucosylated than T125 (YB2 / O)
- T125 (YB2 / O)
- T125 YB2 / O
- RFc ⁇ IIBl-dependent inhibitory functions On the other hand, it only weakly binds human RFc ⁇ lIIAs and is a bad inducer of the RFc ⁇ lIIA-dependent activating functions.
- Concentrations of approximately 15 ⁇ g / ml for T125 (YB2 / O) and 40 ⁇ g / ml for T125 (YB2 / O) His 310 Lys / His 435 Lys are required to induce a 50% inhibition of uptake.
- monoclonal antibody to the RFcylIIA 3G8-PE expressed on the surface of Jurkat-huRFc ⁇ lIIA cells are required to induce a 50% inhibition of uptake.
- a dose of T125 (CHO) greater than 100 ⁇ g / ml (approximately 130 ⁇ g / ml) is necessary to achieve 50% inhibition of the binding of 3G8-PE.
- the double mutant Tl25 (YB20) His 310 Lys / His 435 Lys is incapable of inhibiting the binding of 40 ng / ml of the ATlO-FITC antibody (anti-RFc ⁇ IIA / RFc ⁇ IIB mAb). human) to HA.1.6-huRFc ⁇ IIB1 cells, whereas T125 (CHO) is capable of inducing inhibition of binding of ATlO-FITC antibody to RFc ⁇ lIB1, although this is lower than that induced by T125 (YB2). / O) ( Figure 4D).
- T125 (YB2O) His 310 Lys / His 435 Lys behaves differently from that of T125 (CHO), in terms of interactions with the RFc ⁇ : T125 (YB2O) His 310 Lys / His 435 Lys effectively recruits RFc ⁇ lIIA activators.
- this monoclonal antibody is unable to engage RFcylIB.
- the ability to induce ADCC lysis of Rh-positive RBCs induced by different anti-Ds in the presence of mononuclear cells (effector cell source) and Tegeline (2500 ⁇ g / ml) was compared for different anti-D antibodies.
- the antibody AD1 is an anti-D antibody that does not trigger an ADCC response and thus serves as a negative control.
- T125 antibody has been expressed in two different cell types: YB2 / 0
- T125 antibody was mutated to replace each of its His 310 and His 435 residues with lysine residues (T125 (YB2 / O) His310Lys / His435Lys).
- the mutated antibody Histidine (H310K H435K) induces an ADCC of Rhesus positive red cells, slightly lower than that obtained with the non-mutated antibody T125 (YB2 / O), but much higher AD1. It should be noted that under these experimental conditions, the anti-D control antibody expressed in CHO does not induce or very little ADCC
- Example 7 Structural impact of the mutation of histidines 310 and 435 in Lysine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06841951A EP1974048A1 (fr) | 2005-12-16 | 2006-12-15 | Procede de preparation d' anticorps selectifs des recepteurs fc activateurs |
BRPI0619726-4A BRPI0619726A2 (pt) | 2005-12-16 | 2006-12-15 | método para preparação de anticorpos seletivos para ativação dos receptores fc |
JP2008545046A JP2009519030A (ja) | 2005-12-16 | 2006-12-15 | 活性型Fc受容体に選択的な抗体の製造方法 |
US12/097,022 US20090029393A1 (en) | 2005-12-16 | 2006-12-15 | Method for preparing antibodies selective for activating fc receptors |
AU2006334552A AU2006334552A1 (en) | 2005-12-16 | 2006-12-15 | Method for preparing antibodies selective for activating Fc receptors |
CA002633080A CA2633080A1 (fr) | 2005-12-16 | 2006-12-15 | Procede de preparation d' anticorps selectifs des recepteurs fc activateurs |
IL192145A IL192145A0 (en) | 2005-12-16 | 2008-06-12 | Method for preparing antibodies selective for activating fc receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0512812 | 2005-12-16 | ||
FR0512812A FR2894982A1 (fr) | 2005-12-16 | 2005-12-16 | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007080277A1 true WO2007080277A1 (fr) | 2007-07-19 |
Family
ID=36691715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/002748 WO2007080277A1 (fr) | 2005-12-16 | 2006-12-15 | Procede de preparation d' anticorps selectifs des recepteurs fc activateurs |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090029393A1 (fr) |
EP (1) | EP1974048A1 (fr) |
JP (1) | JP2009519030A (fr) |
KR (1) | KR20080099244A (fr) |
CN (1) | CN101365799A (fr) |
AU (1) | AU2006334552A1 (fr) |
BR (1) | BRPI0619726A2 (fr) |
CA (1) | CA2633080A1 (fr) |
FR (1) | FR2894982A1 (fr) |
IL (1) | IL192145A0 (fr) |
WO (1) | WO2007080277A1 (fr) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1689785A2 (fr) * | 2003-10-20 | 2006-08-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation de cations metalliques pour cristalliser le fragment fc d'un anticorps anti rhésus d |
WO2010033279A3 (fr) * | 2008-06-04 | 2010-06-17 | Macrogenics, Inc. | <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb> |
WO2014125041A1 (fr) | 2013-02-14 | 2014-08-21 | Innate Pharma | Traitement du lymphome t périphérique |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
WO2016030488A1 (fr) | 2014-08-27 | 2016-03-03 | Innate Pharma | Traitement d'une maladie coeliaque |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
WO2017157895A1 (fr) | 2016-03-15 | 2017-09-21 | Innate Pharma | Anticorps anti-mica |
WO2018073363A1 (fr) | 2016-10-21 | 2018-04-26 | Innate Pharma | Traitement avec des agents anti-kir3dl2 |
EP3521312A1 (fr) | 2013-02-20 | 2019-08-07 | Innate Pharma, S.A. | Composé qui se lie spécifiquement à kir3dl2 destiné à être utilisé dans le traitement du lymphome t périphérique |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940616A1 (fr) * | 2008-12-30 | 2010-07-02 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire. |
CN102718836B (zh) * | 2009-04-24 | 2014-04-16 | 上海交通大学医学院附属瑞金医院 | 一种短肽及含有其的免疫抑制剂和应用 |
FR2966043A1 (fr) * | 2010-10-14 | 2012-04-20 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif |
CA2862101A1 (fr) | 2012-02-07 | 2013-08-15 | Innate Pharma | Agents se liant a mica |
CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020098193A1 (en) * | 1997-03-03 | 2002-07-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO2004063351A2 (fr) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes |
FR2861079A1 (fr) * | 2003-10-20 | 2005-04-22 | Lab Francais Du Fractionnement | Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
IL151348A0 (en) * | 2000-04-13 | 2003-04-10 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
-
2005
- 2005-12-16 FR FR0512812A patent/FR2894982A1/fr not_active Withdrawn
-
2006
- 2006-12-15 KR KR1020087017371A patent/KR20080099244A/ko not_active Application Discontinuation
- 2006-12-15 US US12/097,022 patent/US20090029393A1/en not_active Abandoned
- 2006-12-15 CA CA002633080A patent/CA2633080A1/fr not_active Abandoned
- 2006-12-15 WO PCT/FR2006/002748 patent/WO2007080277A1/fr active Application Filing
- 2006-12-15 EP EP06841951A patent/EP1974048A1/fr not_active Withdrawn
- 2006-12-15 JP JP2008545046A patent/JP2009519030A/ja active Pending
- 2006-12-15 BR BRPI0619726-4A patent/BRPI0619726A2/pt not_active IP Right Cessation
- 2006-12-15 AU AU2006334552A patent/AU2006334552A1/en not_active Abandoned
- 2006-12-15 CN CNA2006800510845A patent/CN101365799A/zh active Pending
-
2008
- 2008-06-12 IL IL192145A patent/IL192145A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020098193A1 (en) * | 1997-03-03 | 2002-07-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO2004063351A2 (fr) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes |
FR2861079A1 (fr) * | 2003-10-20 | 2005-04-22 | Lab Francais Du Fractionnement | Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps. |
WO2005040216A2 (fr) * | 2003-10-20 | 2005-05-06 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de cations metalliques pour cristalliser le fragment fc d’un anticorps rhesus d |
Non-Patent Citations (3)
Title |
---|
SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and design of IgG1 variants with improved binding to the FcgammaR", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 6604, XP002271092, ISSN: 0021-9258 * |
SONDERMANN P ET AL: "Crystal structure of the soluble form of the human Fcgamma-receptor IIb: A new member of the immunoglobulin superfamily at 1.7 ANG resolution", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 18, no. 5, March 1999 (1999-03-01), pages 1095 - 1103, XP002363080, ISSN: 0261-4189 * |
WINES B D ET AL: "The IgG Fc contains distinct Fc receptor (FcR) binding sites: The leukocyte receptors Fc[gamma]RI and Fc[gamma]RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 164, no. 10, 15 May 2000 (2000-05-15), pages 5313 - 5318, XP002381581, ISSN: 0022-1767 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1689785A2 (fr) * | 2003-10-20 | 2006-08-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation de cations metalliques pour cristalliser le fragment fc d'un anticorps anti rhésus d |
WO2010033279A3 (fr) * | 2008-06-04 | 2010-06-17 | Macrogenics, Inc. | <sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb> |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US10683364B2 (en) | 2010-03-04 | 2020-06-16 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9714295B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9714296B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9896508B2 (en) | 2010-03-04 | 2018-02-20 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US10730945B2 (en) | 2010-03-04 | 2020-08-04 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and users thereof |
WO2014125041A1 (fr) | 2013-02-14 | 2014-08-21 | Innate Pharma | Traitement du lymphome t périphérique |
EP3255062A1 (fr) | 2013-02-14 | 2017-12-13 | Innate Pharma | Traitement de lymphome t périphériques |
EP3896088A1 (fr) | 2013-02-20 | 2021-10-20 | Innate Pharma | Traitement de lymphome t périphérique |
EP3521312A1 (fr) | 2013-02-20 | 2019-08-07 | Innate Pharma, S.A. | Composé qui se lie spécifiquement à kir3dl2 destiné à être utilisé dans le traitement du lymphome t périphérique |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
WO2016030488A1 (fr) | 2014-08-27 | 2016-03-03 | Innate Pharma | Traitement d'une maladie coeliaque |
WO2017157895A1 (fr) | 2016-03-15 | 2017-09-21 | Innate Pharma | Anticorps anti-mica |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
US11591400B2 (en) | 2016-04-15 | 2023-02-28 | Macrogenics, Inc. | B7-H3 directed antibody drug conjugates |
WO2018073363A1 (fr) | 2016-10-21 | 2018-04-26 | Innate Pharma | Traitement avec des agents anti-kir3dl2 |
Also Published As
Publication number | Publication date |
---|---|
CA2633080A1 (fr) | 2007-07-19 |
KR20080099244A (ko) | 2008-11-12 |
AU2006334552A1 (en) | 2007-07-19 |
US20090029393A1 (en) | 2009-01-29 |
FR2894982A1 (fr) | 2007-06-22 |
EP1974048A1 (fr) | 2008-10-01 |
CN101365799A (zh) | 2009-02-11 |
IL192145A0 (en) | 2008-12-29 |
BRPI0619726A2 (pt) | 2011-10-11 |
JP2009519030A (ja) | 2009-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007080277A1 (fr) | Procede de preparation d' anticorps selectifs des recepteurs fc activateurs | |
TWI781098B (zh) | 新穎的b7-h3-結合分子、其抗體藥物綴合物及其使用方法 | |
CN102666874B (zh) | 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法 | |
CA2542881A1 (fr) | Anticorps possedant un ratio taux de fucose / taux de galactose optimise | |
EA037554B1 (ru) | Анти-lag-3 связывающие белки | |
HU230769B1 (hu) | Módosított effektor-funkciójú polipeptid-változatok | |
AU2016333512A1 (en) | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use | |
WO2020153467A1 (fr) | Nouveaux antigènes du cancer et anticorps desdits antigènes | |
DK2463368T3 (en) | HUMANIZED ANTI-AMYLOID-BETA OLIGOMER ANTIBODY | |
TW202016142A (zh) | 用於治療癌症之組合物及方法 | |
JP2023507388A (ja) | インビボにおける生物学的ターゲティングのための材料及び方法 | |
TW202241507A (zh) | Psma結合蛋白及其用途 | |
TW202227142A (zh) | 生物醫藥組合物及相關方法 | |
JP2024073580A (ja) | Btla抗体 | |
AU2017320457A1 (en) | CD20 antibodies | |
EP3623383A1 (fr) | Protéines de liaison à l'antigène flt3xcd3 bispécifiques améliorées | |
CN117545779A (zh) | 抗ctla-4抗体的用途 | |
CN117616123A (zh) | 抗ctla-4抗体 | |
JP2022538374A (ja) | Pdgf-bおよびpdgf-dに結合する抗原結合分子ならびにその使用 | |
EP1689785A2 (fr) | Utilisation de cations metalliques pour cristalliser le fragment fc d'un anticorps anti rhésus d | |
CA3227515A1 (fr) | Compositions biopharmaceutiques et procede de cartographie peptidique de marquage isotopique stable | |
CN117396513A (zh) | 治疗癌症的联合疗法 | |
CN117580867A (zh) | Psma结合蛋白及其用途 | |
CA3233953A1 (fr) | Polytherapies pour le traitement du cancer | |
CN113975385A (zh) | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008545046 Country of ref document: JP Ref document number: 2633080 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006841951 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006334552 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3561/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680051084.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017371 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006334552 Country of ref document: AU Date of ref document: 20061215 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006334552 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006841951 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12097022 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0619726 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080613 |